> BioLineRx paid Biokine Therapeutics $15 million (€13 million) in cash and stock for a 20% stake in cancer drug BL-8040. The Israeli biotech now owns 80% of the asset. Statement
> GW Pharmaceuticals raised $300 million (€261 million) in a stock offering. Release
> Inventiva delayed anticipated readouts from its trials in NASH and mucopolysaccharidosis type VI. The French biotech is opening additional trial sites. Statement
> Motif Bio penciled in a deal to extend its loan repayment by one year. Release
> Enesi Pharma entered into a deal with Public Health England to develop needle-free solid-dose vaccines. Statement
> Inotrem posted phase 2a data on its septic shock candidate. Release